Brittle bone drug trial falls short on fractures as firm cuts costs

Ultragenyx (NASDAQ: RARE) reported Dec. 29, 2025 that its Phase 3 Orbit (n=159, randomized 2:1) and Cosmic (n=69, randomized 1:1) studies of setrusumab in osteogenesis imperfecta failed to meet the primary endpoint of statistically significant reductions in annualized clinical fracture rate versus placebo or bisphosphonates, although both trials achieved statistically significant improvements in bone mineral density and showed no new safety signals. The company said it will perform further data analyses across other bone-health endpoints and will implement significant expense reductions while relying on revenue from four approved products and preparing for near-term gene therapy and Angelman milestones — a clinical and operational setback likely to prompt investor reassessment of pipeline value and near-term guidance.

Analysis

Market structure: The Phase 3 miss materially weakens RARE’s value proposition for setrusumab (UX143), directly hurting Ultragenyx (RARE) equity and its partner Mereo (MREO) near-term; small-cap OI-focused developers and investors in late-stage single-indication assets are losers while payors and incumbents (bisphosphonate suppliers) face reduced pricing pressure. Competitive dynamics shift modestly toward existing standard-of-care (IV bisphosphonates) and established large-cap bone/rare players (e.g., AMGN’s Evenity franchise resilience), limiting pricing power for a new entrant; supply-demand for OI drugs stays constrained given small patient numbers. Cross-asset: expect widened credit spreads for RARE (higher CDS/bond yields), a 30–70% lift in implied volatility on RARE options over 1–3 months, minimal FX/commodity impact but increased hedging flows in biotech sector ETFs (IBB, XBI) for 1–4 weeks.

Risk assessment: Tail risks include a regulatory rejection or full program termination (low-probability but catastrophic to equity) and adverse class-level reputational spillovers if post-hoc safety signals emerge; conversely, a positive subgroup (pediatric) reanalysis could materially salvage value. Time horizons: immediate (days) — stock repricing and vol spike; short-term (4–12 weeks) — company analyses and expense-cut announcement details; long-term (3–12 months) — program fate, potential divestiture, and upcoming gene therapy/Angelman milestones that could offset losses. Hidden dependencies: reimbursement dynamics, pediatric subgroup statistical power, and partner Mereo funding covenants could drive second-order dilution or asset sale decisions. Key catalysts: additional fracture/bone-health analyses (30–90 days), 10‑Q/earnings cadence (next quarter), and any Mereo announcements on co-development funding.

Trade implications: Direct: establish a tactical short in RARE (3% portfolio net short) or buy a 3-month put spread to capture a 25–40% downside with defined risk; size per risk limits and scale into weakness within 5 trading days. Pair: long AMGN (2% portfolio) vs short RARE (3%) to express safety/scale premium; AMGN benefits from relative certainty and Evenity class incumbency. Options: consider buying 3–6 month RARE puts or put spreads (30–50% OTM) to capture elevated IV; sell short-dated covered calls on existing long biotech positions to harvest premium. Sector rotation: reduce small-cap rare/therapeutic developers by 2–4% and redeploy into large-cap, cash-generative biotechs (AMGN, GILD) and selective gene-therapy platform names ahead of pivotal catalysts.

Contrarian angles: The market is likely over-penalizing RARE on headline miss versus BMD efficacy; if pediatric subgroup or non-fracture clinical endpoints (quality of life, mobility) show robust benefit, the asset could retain niche value for label extension or partnership sale, implying asymmetric upside for patient capital. Historical parallels: other biologics with primary endpoint misses but strong biomarker signals were later salvaged via narrower indications or M&A (example: oncology biomarker-driven re-routes), suggesting a 20–35% recovery scenario contingent on positive secondary analyses within 3–6 months. Unintended consequence: aggressive expense cuts could damage commercial readiness for near-term gene therapy launches, risking revenue offsets — monitor cash runway and guidance revisions as a trigger to adjust sizing.

Key Decisions for Investors

• Establish a tactical net short in RARE equal to ~3% of portfolio within 5 trading days (or equivalent via a 3‑month put spread 30–50% OTM) to capture expected 25–40% downside while limiting capital at risk; cover or reassess after company releases subgroup/secondary analyses (target window 30–90 days).
• Implement a pair trade: short RARE (3% notional) and long AMGN (2% notional) to express downside in small-cap program risk vs large-cap franchise stability; rebalance if AMGN reports material Evenity headwinds or RARE’s pediatric analysis yields statistically significant fracture reduction.
• Reduce aggregate small-cap rare-disease exposure by 2–4% and redeploy into large-cap, cash-generative biotechs (e.g., AMGN, GILD) by 1–2% for defensive carry and lower idiosyncratic risk ahead of sector volatility over next 3–6 months.
• Buy asymmetric optionality: purchase 3–6 month RARE put spreads (limit cost to <2% portfolio risk) and simultaneously set alerts for these catalysts: company data re-analyses (30–90 days), next quarterly filing, and Mereo funding announcements — if any catalyst is positive (statistically significant fracture reduction or partnership), close puts and consider selective long-dated call exposure (6–12 months).